AbbVie Pushes Greater Flexibility With Oral Migraine Preventative Atogepant

Atogepant, if approved, will be the third tool in AbbVie Inc.’s migraine box and the final step in building a franchise around the idea of optionality. The oral CGRP inhibitor is under US FDA review for prevention of episodic migraines, and should it reach the market will compete against a trio of established injectable antibodies. But AbbVie thinks beyond the convenience advantage of the oral option, it will be a more flexible alternative that could be easier to gain new patients.

Looking at final Phase III data presented at the American Association of Neurology annual meeting on 20 April, atogepant’s efficacy is on par with approved CGRP-targeting monoclonal antibodies, Michael Gold, AbbVie’s vice president of development for neuroscience, told Scrip